VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

VJVirtual | Management of Irish ALK+ NSCLC patients with brigatinib

Jarushka Naidoo • 4 Nov 2020
Lung Cancer Non-Small Cell Lung Cancer Brigatinib Crizotinib
ALTA-1L

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

More from Jarushka Naidoo

1:12
Exciting updates at the Gathering around Cancer meeting
Jarushka Naidoo • 4 Nov 2020
3:58
Antibody drug conjugates in lung cancer
Jarushka Naidoo • 23 Apr 2021
4:32
Key NSCLC updates
Jarushka Naidoo • 4 Nov 2020
4:04
BTOG 2021 highlights: translational research in lung cancer
Jarushka Naidoo • 23 Apr 2021

Related Videos

3:02
Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
Heather A. Wakelee • 9 Jun 2021
4:50
IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC
Heather A. Wakelee • 9 Jun 2021
3:28
Bispecific antibodies in lung cancer
Benjamin Besse • 7 Jun 2021
3:28
The future of NSCLC treatment
Benjamin Besse • 7 Jun 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals